Novartis and DSM trim jobs


Pharmaceutical firm Novartis and nutritional products specialist DSM are both set to cut jobs in Switzerland. Novartis’s will lose around 500 support and operational roles, while DSM aims to cut 120 staff. Novartis also plans to close a manufacturing plant in the US, affecting 525 employees.

Novartis says that the loss of patent exclusivity on blood pressure drug Diovan (valsartan) has reduced demand for products produced at the Suffern, New York, site. Following its phased closure over 2–3 years, the buildings will be demolished and equipment transferred elsewhere or sold, although company spokeswoman Julie Masow adds that the company is open to other proposals for the site.

Novartis adds that its planned product launches for 2014 will be accompanied by ‘several hundred’ new jobs in Switzerland, for example in supply chain management for its Sandoz generics arm and manufacturing for over-the-counter products.

DSM’s cuts are the fallout of reorganisation after recent acquisitions. The affected positions will come from both central support and R&D areas.


Related Content

Novartis to shut Horsham site

6 November 2013 Business

news image

UK research centre closure to result in the loss of 371 jobs as firm consolidates its global R&D base

Business roundup

31 March 2010 Business

news image

Industry news, April 2010

Most Read

Lawrencium experiment could shake up periodic table

9 April 2015 Research

news image

Measurement of first ionisation energy confirms electronic configuration but opens up an important debate

Silicon chip spots dangerous pathogens in human blood

10 April 2015 Research

news image

Silicon wafer doped with silver nanoparticles can rapidly identify E. coli in blood

Most Commented

Lawrencium experiment could shake up periodic table

9 April 2015 Research

news image

Measurement of first ionisation energy confirms electronic configuration but opens up an important debate

Big problems with little particles?

9 April 2015 Feature

news image

There is a risk that poor toxicology studies could start undermining the success of nanomaterials, reports Elinor Hughes